www.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-definanzen.net GmbHhttp://images.finanzen.net/images/finanzen_net_neu.gifhttp://www.finanzen.nethttp://www.finanzen.net/nachricht/Ipsen-Monthly-Information-Regarding-the-Total-Number-of-Voting-Rights-and-Total-Number-of-Shares-of-the-Company-2418792 <style type="text/css"> <!-- .bwalignc {text-align: center} .bwalignl {text-align: left} .bwcellpmargin {margin-bottom: 0px; margin-top: 0px} .bwnowrap {white-space: nowrap} .bwpadl0 {padding-left: 0.0px} .bwpadr0 {padding-right: 0.0px} .bwsinglebottom ...http://www.finanzen.net/nachricht/Ipsen-Monthly-Information-Regarding-the-Total-Number-of-Voting-Rights-and-Total-Number-of-Shares-of-the-Company-2418792http://www.finanzen.net/nachricht/Ipsen-Combined-Shareholders-Meeting-of-31-May-2013-2406062 <style type="text/css"> <!-- .bwalignc {text-align: center} .bwlistitemmargb {margin-bottom: 10.0px} --> </style> <!-- sh_cad_1 --> Regulatory News: The Shareholders of the Company are invited to participate in the ...http://www.finanzen.net/nachricht/Ipsen-Combined-Shareholders-Meeting-of-31-May-2013-2406062http://www.finanzen.net/nachricht/IPSEN-Description-of-the-share-repurchase-program-proposed-by-the-Board-of-Directors-to-the-approval-of-the-Combined-Shareholders-Meeting-to-be-held-on-31-May-2013-2392292 <style type="text/css"> <!-- .bwalignc {text-align: center} .bwalignl {text-align: left} --> </style> <p class="bwalignl"> Regulatory News: <!-- sh_cad_1 --> IPSEN (Paris:IPN): <p class="bwalignc"> <b>IPSEN</b> <p ...http://www.finanzen.net/nachricht/IPSEN-Description-of-the-share-repurchase-program-proposed-by-the-Board-of-Directors-to-the-approval-of-the-Combined-Shareholders-Meeting-to-be-held-on-31-May-2013-2392292http://www.finanzen.net/nachricht/Ipsen-s-First-Quarter-2013-Sales-2390453 <style type="text/css"> <!-- .bwalignc {text-align: center} .bwalignl {text-align: left} .bwalignr {text-align: right} .bwcellpmargin {margin-bottom: 0px; margin-top: 0px} .bwlistitemmargb {margin-bottom: 10.0px} .bwmarginl1 {margin-left: 30.0px} .bwnowrap ...http://www.finanzen.net/nachricht/Ipsen-s-First-Quarter-2013-Sales-2390453http://www.finanzen.net/nachricht/Ipsen-expects-Increlex-supply-interruption-due-to-supplier-manufacturing-issues-2390451 <style type="text/css"> <!-- .bwalignc {text-align: center} --> </style> Regulatory News: <!-- sh_cad_1 --> Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced that the supplier of Increlex^®’s(mecasermin ...http://www.finanzen.net/nachricht/Ipsen-expects-Increlex-supply-interruption-due-to-supplier-manufacturing-issues-2390451http://www.finanzen.net/nachricht/Active-Biotech-and-Ipsen-Update-the-Analysis-Plan-for-the-10TASQ10-Trial-Evaluating-Tasquinimod-in-the-Treatment-of-Prostate-Cancer-2390448 <style type="text/css"> <!-- .bwalignc {text-align: center} --> </style> Regulatory News: <!-- sh_cad_1 --> Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) (Paris:IPN) today announced ...http://www.finanzen.net/nachricht/Active-Biotech-and-Ipsen-Update-the-Analysis-Plan-for-the-10TASQ10-Trial-Evaluating-Tasquinimod-in-the-Treatment-of-Prostate-Cancer-2390448http://www.finanzen.net/nachricht/Combined-Shareholders-Meeting-of-Ipsen-on-31-May-2013-Proposals-of-Renewal-of-the-Terms-of-Office-of-Two-Directors-and-Appointment-of-a-New-Director-2389499 <style type="text/css"> <!-- .bwalignc {text-align: center} --> </style> Regulatory News: <!-- sh_cad_1 --> Upon proposal of the Appointments and Governance Committee, the Board of Directors of Ipsen (Paris:IPN) ...http://www.finanzen.net/nachricht/Combined-Shareholders-Meeting-of-Ipsen-on-31-May-2013-Proposals-of-Renewal-of-the-Terms-of-Office-of-Two-Directors-and-Appointment-of-a-New-Director-2389499http://www.finanzen.net/nachricht/PeptiDream-and-Ipsen-Enter-into-a-Collaboration-for-Advancing-Drug-Discovery-Efforts-for-Peptides-to-Treat-Serious-Disease-2362352 <style type="text/css"> <!-- .bwalignc {text-align: center} .bwalignl {text-align: left} --> </style> <p class="bwalignl"> Regulatory News: <!-- sh_cad_1 --> PeptiDream Inc., a Tokyo-based pharmaceutical company (PeptiDream), ...http://www.finanzen.net/nachricht/PeptiDream-and-Ipsen-Enter-into-a-Collaboration-for-Advancing-Drug-Discovery-Efforts-for-Peptides-to-Treat-Serious-Disease-2362352http://www.finanzen.net/nachricht/IPSEN-SA-Monthly-Information-Regarding-the-Total-Number-of-Voting-Rights-and-Total-Number-of-Shares-of-the-Company-2356034 <style type="text/css"> <!-- .bwalignc {text-align: center} .bwalignl {text-align: left} .bwcellpmargin {margin-bottom: 0px; margin-top: 0px} .bwnowrap {white-space: nowrap} .bwpadl0 {padding-left: 0.0px} .bwpadr0 {padding-right: 0.0px} .bwsinglebottom ...http://www.finanzen.net/nachricht/IPSEN-SA-Monthly-Information-Regarding-the-Total-Number-of-Voting-Rights-and-Total-Number-of-Shares-of-the-Company-2356034http://www.finanzen.net/nachricht/The-Ipsen-Group-Publishes-Its-2012-Registration-Document-2341514 <style type="text/css"> <!-- .bwalignc {text-align: center} .bwlistitemmargb {margin-bottom: 10.0px} .bwmarginl1 {margin-left: 30.0px} --> </style> <!-- sh_cad_1 --> Regulatory News : Ipsen (Paris:IPN) (Euronext: IPN; ADR: ...http://www.finanzen.net/nachricht/The-Ipsen-Group-Publishes-Its-2012-Registration-Document-2341514